Terms: = Bone cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Staging
23 results:
1. Clinical, Radiographic, Pathologic Characterization and Survival Outcomes of Nuclear Protein of the Testis Carcinoma.
Virarkar M; Mallery M; Saleh M; Ramani NS; Morani AC; Bhosale P
J Comput Assist Tomogr; 2021 May-Jun 01; 45(3):431-441. PubMed ID: 34297512
[TBL] [Abstract] [Full Text] [Related]
2. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
[TBL] [Abstract] [Full Text] [Related]
3. Use of 18F-FDG PET/CT as an Initial staging Procedure for Stage II-III Breast cancer: A Multicenter Value Analysis.
Hyland CJ; Varghese F; Yau C; Beckwith H; Khoury K; Varnado W; Hirst GL; Flavell RR; Chien AJ; Yee D; Isaacs CJ; Forero-Torres A; Esserman LJ; Melisko ME
J Natl Compr Canc Netw; 2020 Nov; 18(11):1510-1517. PubMed ID: 33152704
[TBL] [Abstract] [Full Text] [Related]
4. Do patients who undergo multiparametric MRI for prostate cancer benefit from additional staging imaging? Results from a statewide collaborative.
Eyrich NW; Tosoian JJ; Drobish J; Montie JE; Qi J; Kim T; Noyes SL; Moriarity AK; Lane BR;
Urol Oncol; 2020 Jul; 38(7):636.e13-636.e19. PubMed ID: 32067844
[TBL] [Abstract] [Full Text] [Related]
5. staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.
Malani R; Bhatia A; Wolfe J; Grommes C
Leuk Lymphoma; 2019 Sep; 60(9):2278-2282. PubMed ID: 30628502
[TBL] [Abstract] [Full Text] [Related]
6. [Cartilage tumors : Pathology and radiomorphology].
Uhl M; Herget G; Kurz P
Radiologe; 2016 Jun; 56(6):476-88. PubMed ID: 27233920
[TBL] [Abstract] [Full Text] [Related]
7. Who dies from prostate cancer?
Patrikidou A; Loriot Y; Eymard JC; Albiges L; Massard C; Ileana E; Di Palma M; Escudier B; Fizazi K
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):348-52. PubMed ID: 25311767
[TBL] [Abstract] [Full Text] [Related]
8. staging and evaluation of neoadjuvant chemotherapy response with ¹⁸F-FDG PET/CT in NUT-midline carcinoma in a child: a case report and review of the literature.
Ciftci E; Demirsoy U; Anik Y; Gorur G; Corapcioglu F; Demir H
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):53-5. PubMed ID: 25304847
[TBL] [Abstract] [Full Text] [Related]
9. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract] [Full Text] [Related]
10. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract] [Full Text] [Related]
11. The trend of managing prostate cancer in Taiwan.
Wong WY; Chen SC; Chueh SC; Chen J
Int J Urol; 2004 Jul; 11(7):510-4. PubMed ID: 15242360
[TBL] [Abstract] [Full Text] [Related]
12. Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.
Wolff JM; Rohde D; Borchers H; Jakse G
Anticancer Res; 2000; 20(6D):5003-5. PubMed ID: 11326658
[TBL] [Abstract] [Full Text] [Related]
13. Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR.
Albers P; Ko Y; Wardelmann E; Schmidt D; Adam M; Vetter H; Müller SC
Anticancer Res; 2000; 20(3B):2107-11. PubMed ID: 10928161
[TBL] [Abstract] [Full Text] [Related]
14. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Borchers H; Boekels O; Jakse G
Anticancer Res; 1999; 19(4A):2653-5. PubMed ID: 10470213
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate.
Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G
Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976
[TBL] [Abstract] [Full Text] [Related]
16. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract] [Full Text] [Related]
17. Diagnostic imaging of malignant cartilage tumors.
Masciocchi C; Sparvoli L; Barile A
Eur J Radiol; 1998 May; 27 Suppl 1():S86-90. PubMed ID: 9652507
[TBL] [Abstract] [Full Text] [Related]
18. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L
Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
[TBL] [Abstract] [Full Text] [Related]
19. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase.
Wolff JM; Ittel TH; Boeckmann W; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2995-7. PubMed ID: 9329584
[TBL] [Abstract] [Full Text] [Related]
20. Prostate specific antigen in the diagnosis and staging of prostate cancer.
Jung P; Wolff JM; Mattelaer P; Jakse G
Acta Urol Belg; 1996 Sep; 64(3):1-6. PubMed ID: 8946774
[TBL] [Abstract] [Full Text] [Related]
[Next]
